Anifrolumab Now Covered Under BC PharmaCare for Lupus Treatment
Expanded Access for Adults with Moderate to Severe
Systemic Lupus Erythematosus:
Anifrolumab is now listed under BC PharmaCare’s Limited Coverage drug formulary.
Anifrolumab (Saphnelo) is now listed under BC PharmaCare’s Limited Coverage drug formulary, offering publicly funded access to eligible patients aged 18 and older living with moderate to severe systemic lupus erythematosus (SLE). This provincial listing is an important advancement in supporting equitable access to treatment in British Columbia.
What Is Anifrolumab?
Expanded Access to Lupus Treatment in British Columbia
Anifrolumab (Saphnelo) is a medication approved to treat adults with moderate to severe lupus who are taking other lupus treatments.
In clinical studies, Saphnelo helped reduce overall disease activity, including symptoms affecting the joints, muscles, and skin. Some people noticed improvements just a few weeks after starting treatment.
It’s also the only treatment of its kind approved for lupus that has been shown to help patients use lower doses of steroids, which can reduce long-term side effects. People taking Saphnelo experienced fewer lupus flares compared to those who didn’t add it to their regular medications.
Who Is Eligible for Coverage?
Coverage for Anifrolumab is available through BC PharmaCare’s Limited Coverage list. Eligibility is based on criteria outlined by the province and typically requires that the prescribing physician confirm disease severity and previous treatment response.
Learn more here: Limited Coverage Drugs – Anifrolumab
Why This Matters
Systemic lupus erythematosus is a complex autoimmune disease that can cause widespread inflammation and organ damage. For many patients, treatment options are limited. Public coverage of Anifrolumab in BC represents a step forward in improving care for individuals who need advanced therapies to manage disease progression and enhance quality of life.
Our Ongoing Commitment
Lupus Canada applauds this decision by BC PharmaCare and continues to advocate for consistent, equitable access to lupus treatments across all provinces and territories. While this milestone brings hope to many in BC, we know the work isn’t done.
We remain committed to ensuring that all Canadians living with lupus have access to the care and medications they need to live well.
Explore Your Treatment Options
If you or someone you know is living with lupus, speak with your healthcare provider to learn whether Anifrolumab (Saphnelo) may be a suitable treatment option. Understanding the benefits of new therapies can empower better health decisions.